Table 3.
Univariate and multivariate analyses of time to treatment failure
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
| Treatment | ||||||
| Observation | 1.00 | .8463 | 1.00 | .8342 | ||
| R‐maintenance | 1.04 | (0.71, 1.51) | 0.96 | (0.65, 1.42) | ||
| Gender | ||||||
| Female | 1.00 | .5929 | 1.00 | .4896 | ||
| Male | 1.10 | (0.77, 1.57) | 1.13 | (0.79, 1.62) | ||
| Age | ||||||
| 20‐59 | 1.00 | .6018 | 1.00 | .8259 | ||
| 60+ | 1.10 | (0.77, 1.59) | 1.05 | (0.70, 1.56) | ||
| Carlson comorbidity index | ||||||
| 0 | 1.00 | .7463 | 1.00 | .7216 | ||
| 1 | 0.85 | (0.53, 1.36) | 0.83 | (0.51, 1.34) | ||
| 2+ | 1.06 | (0.63, 1.76) | 1.01 | (0.59, 1.71) | ||
| Ann Arbor stage | ||||||
| II‐III | 1.00 | .1597 | 1.00 | .1159 | ||
| IV | 1.29 | (0.91, 1.84) | 1.34 | (0.93, 1.91) | ||
| Practice setting | ||||||
| Medical center | 1.00 | .2115 | 1.00 | .1337 | ||
| Others | 0.76 | (0.50, 1.17) | 0.72 | (0.46, 1.11) | ||
| Induction treatment | ||||||
| R‐CHOP | 1.00 | .2173 | 1.00 | .1107 | ||
| R‐others | 1.25 | (0.88, 1.78) | 1.36 | (0.93, 1.99) | ||
| Rituximab cycles in induction treatment | ||||||
| 4‐6 cycles | 1.00 | .0747 | 1.00 | .0357a | ||
| 7‐8 cycles | 0.69 | (0.46, 1.04) | 0.64 | (0.42, 0.97) | ||
R‐maintenance, rituximab maintenance.
a
P‐value is <.05.